← Back to patent-cliff list
Cyclosporine/Loteprednol Etabonate
Tier C — Watch / tradeCyclosporine/Loteprednol Etabonate
Research Insight Llc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Calcineurin, Mitocliondrial permeability transition pore, GR, PLA2G4A, PGY1
Indications (approved)：Dry eye disease
Regional status
US
Phase III
2022-06-03
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cyclosporine/Loteprednol Etabonate?
Approved indications include: Dry eye disease.
When does the Cyclosporine/Loteprednol Etabonate patent expire?
No public expiry year is available for Cyclosporine/Loteprednol Etabonate yet; this page updates once verified.
How do I get a quote for Cyclosporine/Loteprednol Etabonate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05